Qi Liu

Merck & Co., Inc., Rahway, NJ, USA (United States) ORCID: 0000-0001-6348-2498

1

h-index

1

Publications

1,394

Citations

Publications

1 shown

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong‐Mu Sun , Lin Shen , Manish A. Shah +22 more

Merck Sharp & Dohme.

2021 The Lancet 1394 citations

Frequent Co-Authors

Jong‐Mu Sun

Samsung Medical Center

Lin Shen

Peking University

Manish A. Shah

Massachusetts Institute of Technology

Peter C. Enzinger

Dana-Farber Cancer Institute

Antoine Adenis

Centre Oscar Lambret

Toshihiko Doi

National Cancer Center Hospital East

Researcher Info

h-index: 1
Publications: 1
Citations: 1,394
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-6348-2498

Impact Metrics

h-index 1

h-index: Number of publications with at least h citations each.

Academic Output Over Time